HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Macular Degeneration (Age-Related Maculopathy)

Subscribe to New Research on Macular Degeneration

Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.

Also Known As:

Age-Related Maculopathy; Age-Related Macular Degeneration; Age-Related Maculopathies; Macular Dystrophy; Maculopathies, Age-Related; Age Related Macular Degeneration; Age Related Maculopathies; Age Related Maculopathy; Age-Related Macular Degenerations; Degeneration, Age-Related Macular; Degeneration, Macular; Degenerations, Age-Related Macular; Degenerations, Macular; Dystrophies, Macular; Dystrophy, Macular; Macular Degeneration, Age-Related; Macular Degenerations; Macular Degenerations, Age-Related; Macular Dystrophies; Maculopathies, Age Related; Maculopathy, Age Related; Maculopathy, Age-Related

Networked: 7077 relevant articles (504 outcomes, 1121 trials/studies)

Relationship Network

Disease Context: Research Results

Eye Diseases: 2132
- Retinal Diseases: 1278
  - Retinal Degeneration: 2246
    - Macular Degeneration: 7077

Related Diseases

1.	Choroidal Neovascularization
2.	Diabetic Retinopathy (Retinopathy, Diabetic)
3.	Cataract (Cataracts)
4.	Hemorrhage
5.	Neoplasms (Cancer)

Experts

1.	Schmidt-Erfurth, Ursula: 57 articles (01/2016 - 09/2002)
2.	Mitchell, Paul: 55 articles (12/2015 - 05/2002)
3.	Guymer, Robyn H: 55 articles (09/2015 - 12/2002)
4.	Klein, Ronald: 55 articles (02/2015 - 10/2002)
5.	Kaiser, Peter K: 53 articles (01/2016 - 03/2003)
6.	Jonas, Jost B: 52 articles (01/2015 - 06/2002)
7.	Freund, K Bailey: 48 articles (01/2016 - 02/2002)
8.	Holz, Frank G: 44 articles (12/2015 - 02/2002)
9.	Klein, Barbara E K: 43 articles (02/2015 - 10/2002)
10.	Chakravarthy, Usha: 42 articles (10/2015 - 03/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Macular Degeneration:

1.	ranibizumab (Lucentis)FDA Link 07/01/2012 - "In the ranibizumab group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity (Snellen equivalent) with typical age-related macular degeneration (22 eyes) and polypoidal choroidal vasculopathy (18 eyes) statistically significantly (P < 0.0001, P = 0.015, respectively) improved from 0.17 (20/29) and 0.14 (20/28) at baseline to 0.07 (20/24) and 0.07 (20/24) at Month 12, respectively (mean numbers of treatments, 4.6 and 4.9). " 01/01/2012 - "Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection." 12/01/2011 - "Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥ 3-line BCVA loss during the first year of treatment." 07/01/2014 - "and (2) Is a higher dose of ranibizumab (2.0 mg/0.05 mL) more effective in treating PCV than the current dose (0.5 mg/0.05 mL) approved for treatment of age-related macular degeneration? " 05/01/2013 - "Intravitreal ranibizumab for the treatment of exudative age-related macular degeneration is effective for stabilizing vision in patients with PED, but it may be better tolerated in patients with serous PED. "
2.	bevacizumab FDA Link 10/01/2012 - "Prompt intravitreal bevacizumab treatment for newly diagnosed exudative age-related macular degeneration in patients with good initial best-corrected visual acuity is associated with sustained or improved vision and a good safety profile. " 06/01/2007 - "To evaluate the effect of systemic bevacizumab (Avastin) therapy on pigment epithelial detachment (PED) secondary to age-related macular degeneration (AMD) and to identify prognostic factors for PED regression and improvement in best corrected visual acuity (BCVA). " 11/01/2010 - "To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA). " 01/01/2009 - "Giant PED secondary to exudative age-related macular degeneration can be successfully treated with intravitreal bevacizumab." 10/01/2013 - "To study prospectively the safety and efficacy of intravitreal bevacizumab for eyes with neovascular age-related macular degeneration with baseline visual acuity better than 70 letters (Snellen equivalent better than 20/40). "
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/01/2015 - "Anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related macular degeneration (nAMD) have proven efficacy at a study-population level, although individual patient responses vary, with most of the patients responding well to anti-VEGF therapies, while a few respond poorly. " 03/01/2012 - "Monthly dosing with inhibitors of vascular endothelial growth factor (VEGF) results in stable or improved visual acuity in most patients with neovascular age-related macular degeneration. " 01/01/2009 - "Since anti-VEGF treatment has been proven to achieve a significant improvement of visual acuity in a cohort of patients with neovascular age-related macular degeneration (AMD), macular surgery and particularly the macular translocation with 360 degrees retinotomy (FMT: full macular translocation) have lost their former popularity. " 09/01/2011 - "We retrospectively studied 40 eyes of 40 patients with neovascular age-related macular degeneration who were treated successfully with intravitreal anti-vascular endothelial growth factor injection. " 12/01/2008 - "Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. "
4.	1-phenyl-3,3-dimethyltriazene (PDT)IBA 06/01/2012 - "Although after PDT final BCVA was significantly worse from baseline, it may also be beneficial for some patients with neovascular age-related macular degeneration." 10/01/2008 - "Combination IVT treatment with PDT seemed to be more effective for managing neovascular age-related macular degeneration, but long-term analysis failed to demonstrate functional benefits." 10/01/2007 - "Understanding the intracellular signaling mechanisms of apoptosis in PDT may lead to more selective and effective treatment of CNV secondary to age-related macular degeneration." 01/01/2009 - "Combining PDT with the standard age-related macular degeneration protocol is an effective treatment for CCH in terms of resolution of exudative subretinal fluid and recovery of VA. " 07/01/2004 - "Targeted PDT for CNV is feasible and may offer a qualitative improvement in current treatments for patients with age-related macular degeneration. "
5.	Retinaldehyde (Retinal)IBA 06/01/2014 - "To determine the sensitivity of the Cirrus high-definition (HD) 5-line raster scans for detecting retinal fluid in neovascular age-related macular degeneration when using the spectral domain optical coherence tomography macular cubes as a gold standard. " 03/01/2014 - "It is a potential new therapeutic for atrophic age-related macular degeneration (AMD) and other retinal degenerative disorders. " 07/01/2005 - "Neovascular age-related macular degeneration (ARMD) with retinal angiomatous proliferation (RAP) has a poor natural history and the efficacy of any treatment has not yet been established. " 12/01/2012 - "Retinal spectral domain optical coherence tomography in early atrophic age-related macular degeneration (AMD) and a new metric for objective evaluation of the efficacy of ocular nutrition." 05/01/2011 - "The data suggest that NACA may be a novel treatment in rescuing retinal function and preventing vision loss secondary to retinal degenerative diseases, including age-related macular degeneration."
6.	verteporfin (Visudyne)FDA Link 08/01/2004 - "The Verteporfin in Age-related Macular Degeneration (VAM) Study was designed to provide expanded access to verteporfin therapy after beneficial results for these cases were reported but before regulatory approval in North America. " 02/01/2010 - "Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration." 01/01/2010 - "For translation to clinical use, it is an advantage that BPD-MA (verteporfin), a second-generation photosensitizer, is already approved to treat age-related macular degeneration. " 02/01/2009 - "Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration." 07/01/2008 - "The photosensitizer verteporfin is approved for the therapy of neovascularizations, such as age-related maculopathy. "
7.	pegaptanib FDA Link 12/30/2004 - "Pegaptanib appears to be an effective therapy for neovascular age-related macular degeneration. " 07/01/2005 - "Pegaptanib was effective and safe without a dose-response relation in neovascular, age-related, macular degeneration." 12/01/2010 - "To assess the efficacy of pegaptanib as maintenance therapy in neovascular age-related macular degeneration (NV-AMD) patients after induction therapy. " 09/01/2007 - "Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration." 09/01/2006 - "Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration."
8.	afliberceptIBA 03/01/2015 - "Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration." 12/01/2015 - "To prospectively assess the safety and efficacy of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration (nAMD). " 10/01/2015 - "Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). " 05/01/2015 - "To investigate the efficacy of periodic injection of aflibercept in each subtype of age-related macular degeneration (AMD) and to explore the predictive factors for visual outcome in clinical settings. " 01/01/2015 - "In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline. "
9.	LuteinIBA 10/01/2008 - "Metabolites of lutein are highly concentrated in the human macula and are known to provide protection against age-related macular degeneration. " 02/01/2013 - "Lutein and DHA supplementation is effective in increasing the MPOD and may aid in prevention of age related macular degeneration." 08/01/2011 - "Lutein has been shown to be protective against age-related macular degeneration; however, the antiinflammatory and antioxidant effects of this carotenoid in aortas are less known. " 08/01/2004 - "Lutein may be protective against diseases such as age-related macular degeneration (ARMD). " 01/01/2014 - "The conduct of this meta-analysis aimed at examining the individual role of lutein as a dietary supplement in improving conditions of age-related macular degeneration (AMD) from the data generated from randomized controlled trials (RCTs). "
10.	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 06/01/2001 - "Animal models, in vitro assays and pilot clinical studies suggest that intravitreal triamcinolone acetonide may be useful in the treatment of age-related macular degeneration. " 09/01/2000 - "Whilst animal studies and a pilot clinical trial suggest that intravitreal triamcinolone acetonide (TA) may be useful in the treatment of age-related macular degeneration (AMD), its mode of action remains to be fully elucidated. " 01/01/2006 - "To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). " 01/01/2000 - "Intravitreal triamcinolone acetonide may provide short-term improvement in visual acuity and fundus findings in exudative macular degeneration. " 01/01/2012 - "To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been performed. "

Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy) 01/01/2003 - "Photodynamic therapy in people with choroidal neovascularisation due to age-related macular degeneration is effective in preventing visual loss. " 01/01/2001 - "Photodynamic therapy in people with classic choroidal neovascularisation due to age-related macular degeneration is effective in preventing visual loss. " 01/01/2000 - "Photodynamic therapy in people with classic choroidal neovascularisation due to age-related macular degeneration is effective in preventing visual loss. " 04/01/2013 - "To investigate the factors associated with recurrence following remission of at least 12 months after photodynamic therapy in patients with age-related macular degeneration (AMD). " 04/01/2013 - "[Background factors of recurrence after remission maintenance with photodynamic therapy for age-related macular degeneration]."
2.	Lasers (Laser) 10/01/2003 - "Prophylactic laser treatment in early age-related maculopathy: an 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications." 08/01/2014 - "The aim of the study was the analysis of reticular drusen (RDR) in patients with age-related macular degeneration using simultaneous confocal scanning laser ophthalmoscopy (cSLO) and spectral domain optical coherence tomography (SD-OCT) at different time points. " 03/01/2013 - "The aim of this study was to identify potential predictive markers in confocal scanning laser ophthalmoscopy (cSLO)-based imaging for tears of the retinal pigment epithelium (RPE) in the presence of pigment epithelial detachments (PED) due to age-related macular degeneration (AMD). " 05/01/2011 - "Retinal pigment epithelium tears secondary to age-related macular degeneration: a simultaneous confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography study." 02/01/2011 - "In the Complications of Age-related Macular Degeneration (AMD) Prevention Trial (CAPT), 1 eye of each participant was randomly assigned to laser treatment and the contralateral eye was assigned to observation to evaluate whether laser treatment of drusen could prevent vision loss. "
3.	Injections 09/01/2014 - "To assess the safety and efficacy of multiple injections of 0.5 and 2.0 mg conbercept using variable dosing regimens in patients with neovascular age-related macular degeneration (AMD). " 01/01/2016 - "A 65-year-old male patient presented with a diagnosis of exudative age-related macular degeneration of his left eye and unsuccessful response to eight antiangiogenic injections. " 04/01/2015 - "Most injections were performed to treat exudative age-related macular degeneration. " 10/01/2014 - "There have been enormous advances in the past decade for the treatment of age-related macular degeneration (AMD); however, these treatments are expensive and require frequent follow-up and injections which place a tremendous burden on both the healthcare system and patients. " 11/01/2012 - "Strategies leading to the long-term suppression of inappropriate ocular angiogenesis are required to avoid the need for repetitive monthly injections for treatment of diseases of the eye, such as age-related macular degeneration (AMD). "
4.	Intravitreal Injections 04/01/2015 - "The evaluation of the safety and preliminary efficacy of 125 μg ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD). " 05/01/2009 - "To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD). " 11/01/2015 - "To study the relation between the interval from diagnosis to initiation of intravitreal injection therapy and visual outcome in neovascular age-related macular degeneration (nAMD) and to report changes over time in fellow-eye status. " 09/01/2015 - "Two or three systematic intravitreal injections (IVT) may be prescribed in a PRN approach to treat an exudative recurrence of neovascular age-related macular degeneration (AMD), according to the phenotype. " 01/01/2013 - "To describe a previously unrecognized complication of intravitreal injection in a patient with exudative macular degeneration and vitreomacular adhesion. "
5.	Light Coagulation 03/01/2000 - "35 membranes, from a consecutive series of surgically removed choroidal neovascular membranes in age related macular degeneration, were classified as classic or occult following the guidelines of the Macular Photocoagulation Study. " 10/01/1999 - "Photocoagulation of subfoveal choroidal neovascular membranes in age related macular degeneration: the impact of the macular photocoagulation study in the United Kingdom and Republic of Ireland." 02/01/1995 - "To determine the percent of cases with all primary forms of exudative age-related macular degeneration that are eligible for treatment by the Macular Photocoagulation Study (MPS) guidelines in a retina clinic serving both as a primary care center and as a referral center. " 02/01/1995 - "The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration." 09/01/1994 - "Individuals with age-related macular degeneration and new subfoveal CNV or recurrent subfoveal CNV enrolled in the Foveal Photocoagulation Studies of the Macular Photocoagulation Study. "